Vertex Pharmaceuticals Incorporated ($VRTX) Stock Forecast: Up 10.5% Today

What is Vertex Pharmaceuticals Incorporated?

Vertex Pharmaceuticals Inc. (VRTX): Vertex Pharmaceuticals is a biotechnology company known for its innovative treatments for cystic fibrosis and other diseases. Today, the stock had a strong bullish movement in the market.

Why is Vertex Pharmaceuticals Incorporated going up?

VRTX stock is up 10.5% on Mar 10, 2026 18:06

• Vertex Pharmaceuticals stock surged 5% after successful Phase 3 trial results for its kidney disease drug, povetacicept, showing promising efficacy and safety profile.
• The company's $4.9 billion acquisition of a biotech company focused on kidney disease is nearing an important milestone, suggesting potential positive outcomes for its investment.
• Increased stake by Capital Research Global Investors and positive reactions from analysts indicate growing confidence in Vertex's pipeline and future commercial prospects.
• Market Linked Securities offering by Goldman Sachs Group Inc. linked to Adobe Inc. and CoreWeave, Inc. stocks may have also influenced positive market sentiment towards Vertex Pharmaceuticals, contributing to its bullish movement.

VRTX Price Chart

VRTX Technical Analysis

VRTX News

Form FWP GOLDMAN SACHS GROUP INC Filed by: GOLDMAN SACHS GROUP INC

This Form FWP filing by Goldman Sachs Group Inc. details a new Market Linked Securities offering with auto-callable features, leveraged upside participation, and contingent downside risk, linked to the performance of Adobe Inc. and CoreWeave, Inc. common stocks. The document outlines the terms, hypothetical payout profiles, key dates, and important risk factors associated with this complex investment product. It also directs potential investors to read the accompanying preliminary pricing supplement and other related documents for comprehensive information.

https://www.streetinsider.com/SEC+Filings/Form+FWP+GOLDMAN+SACHS+GROUP+INC+Filed+by%3A+GOLDMAN+SACHS+GROUP+INC/26137416.html

Vertex's $4.9B bet nears payoff with important milestone

Vertex Pharmaceuticals Inc.'s nearly two-year-old $4.9 billion acquisition of a Seattle-based biotech, which aimed to develop a kidney disease drug, is approaching a significant milestone. This acquisition was the largest in the Boston company's history, highlighting its substantial investment in this therapeutic area. The article suggests that this major bet is now close to yielding results.

https://www.nbcboston.com/boston-business-journal/vertexs-4-9b-bet-nears-payoff-with-important-milestone/3913311/

Vertex Pharmaceuticals Stock Pops 5% On Successful Late Stage Kidney Disease Drug Trial

Vertex Pharmaceuticals (VRTX) stock rose 5% following positive Phase 3 trial results for its drug povetacicept, targeting IgA nephropathy. The drug significantly reduced proteinuria and showed a clean safety profile, with Vertex planning to submit its biologics license application ahead of schedule. Analysts have reacted positively, raising price targets, as this marks a potential major new commercial franchise beyond the company's dominant cystic fibrosis business.

https://www.tikr.com/blog/vertex-pharmaceuticals-vrtx-stock-pops-5-on-successful-late-stage-kidney-disease-drug-trial

Capital Research Global Investors Increases Stake in Vertex Pharmaceuticals Incorporated $VRTX

Capital Research Global Investors has increased its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 2.8% during the third quarter, now owning 6.52% of the company's stock valued at $6.48 billion. This makes Vertex Pharmaceuticals the 17th largest holding for the fund. Other hedge funds have also modified their holdings, while recent news highlights positive sentiment around Vertex's RAINIER Phase 3 interim analysis for povetacicept.

https://www.marketbeat.com/instant-alerts/filing-capital-research-global-investors-increases-stake-in-vertex-pharmaceuticals-incorporated-vrtx-2026-03-10/

S&P 500 Futures Steady in Premarket Trading; Vertex Pharmaceuticals, UFP Industries Lead

S&P 500 futures are stable in premarket trading. Vertex Pharmaceuticals Inc. (VRTX) is up 6.2%, and UFP Industries Inc. (UFPI) is up 5.0% ahead of the U.S. stock market open.

https://www.barrons.com/articles/s-p-500-futures-steady-in-premarket-trading-vertex-pharmaceuticals-ufp-industries-lead-c23d401b?gaa_at=eafs&gaa_n=AWEtsqeC709q3m_a2MHydgEXVesxfHV2xIdEuKSyXoKWlh_2pe_x32Pp3AUD&gaa_ts=69b00934&gaa_sig=ro7cNCNGRS_e7KkudtNfbUgeNjQYG9BV5gWRWG8YqlPps-ODO_bSqmcVDVof9bLIA5IrBCZJwjetVe_XgAnDkQ%3D%3D

Trending Today

Groupon Inc. ($GRPN) Stock Forecast: Down 5.2% Today

Amplitude Inc. ($AMPL) Stock Forecast: Down 5.2% Today

Ambarella Inc. ($AMBA) Stock Forecast: Down 5.7% Today

PTC Inc. ($PTC) Stock Forecast: Down 5.3% Today

LyondellBasell Industries NV Class A (Netherlands) ($LYB) Stock Forecast: Up 5.3% Today

Teleflex Incorporated ($TFX) Stock Forecast: Up 5.1% Today

Southwest Airlines Company ($LUV) Stock Forecast: Down 5.3% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Down 6.7% Today

Blink Charging Co. ($BLNK) Stock Forecast: Down 12.6% Today

Alaska Air Group Inc. ($ALK) Stock Forecast: Down 5.5% Today

Vertex Pharmaceuticals Incorporated Price History

03.11.2025 - VRTX Stock was up 5.9%

• An upgrade from a major financial institution to an Overweight rating for Vertex's stock and an increase in the price target, driven by the potential of the kidney pipeline candidates Pove and Inaxaplin, have boosted investor confidence in the company's expansion into new treatment areas.
• The addition of Duncan McKechnie as the Executive Vice President and Chief Commercial Officer brings extensive experience in commercial operations to Vertex, potentially enhancing the company's global commercial strategies and market presence.
• Vertex's solid financial standing, positive results from clinical trials of its kidney therapy, and expectations of growth in revenue and earnings from 2025 to 2035 have all contributed to the positive market outlook for the stock.
• Despite concerns about the company's reliance on cystic fibrosis treatments and pricing challenges, investors are monitoring Vertex's valuation, growth projections, and research and development efforts to evaluate its potential for growth in the competitive pharmaceutical industry.

03.11.2025 - VRTX Stock was up 5.6%

• The appointment of Duncan McKechnie as Vertex Pharmaceuticals' Executive Vice President and Chief Commercial Officer likely instilled confidence in investors, indicating strong leadership and strategic vision within the organization.
• Akeso's ambitious research and development (R&D) objectives and successful endeavors with Ivonescimab may have had a positive influence on Vertex's stock performance, showcasing the competitive landscape and potential for groundbreaking advancements in the industry.
• The collaboration between Regeneron Pharmaceuticals and Tessera Therapeutics to collaborate on a gene therapy for a rare medical condition likely fostered optimism in the biotech field, indirectly benefiting Vertex amid the broader positive sentiment towards healthcare innovations.
• Despite a Zacks Rank #3 (Hold) recommendation for Vertex, the prevailing optimistic outlook for pharmaceutical firms and the industry's growth potential possibly contributed to the upward momentum in the company's stock.

03.11.2025 - VRTX Stock was up 6.3%

• VRTX stock surged by 6.2% following an upgrade to "Overweight" with a new price target of $516, driven by optimism surrounding the potential of Vertex's kidney drug pipeline, specifically Pove and Inaxaplin.
• The upgrade reflects confidence in Vertex's pipeline diversity and the shift towards valuing drugmakers based on long-term chronic disease solutions, beyond the traditional cystic fibrosis franchise.
• The appointment of Duncan McKechnie as the Executive Vice President and Chief Commercial Officer also signals strong leadership within the company, further boosting investor confidence in Vertex's strategic direction and commercial activities.
• Despite facing challenges in its cystic fibrosis business, Vertex's promising clinical trial data for its investigational kidney therapy, povetacicept, is expected to drive accelerated revenue and earnings growth between 2025 and 2035, positioning the company for long-term success in the pharmaceutical industry.

04.10.2025 - VRTX Stock was up 0.5%

• VRTX had a strong bullish movement today.
• The company is expected to report higher Q3 earnings, with analysts revising their forecasts ahead of the earnings call.
• Over the past 15 years, Vertex Pharmaceuticals has significantly outperformed the market, showcasing an average annual return of 18.0%.
• Despite a slight -1.23% dip in stock price recently, the overall market sentiment remains positive for Vertex Pharmaceuticals.

13.01.2026 - VRTX Stock was up 8.0%

• Vertex Pharmaceuticals (VRTX) saw a notable upward trend in the market due to positive analyst evaluations and coverage, indicating substantial growth prospects in its renal pipeline and non-cystic fibrosis products.
• The company's impressive financial results in Q4 2025, showcasing significant revenue growth and successful product introductions, contributed to the upbeat market movement.
• Analysts are closely observing Vertex's kidney franchise and advancements in its non-opioid painkiller Journavx, expecting promising outcomes and sustained momentum in the upcoming period.
• The market's favorable reaction to Vertex's strategic foray into gene therapy and pain management, along with its strong performance in the core cystic fibrosis franchise, likely underpinned the positive trajectory of VRTX stock.

13.01.2026 - VRTX Stock was up 5.4%

• The notable surge in Vertex Pharmaceuticals' stock price can be attributed to its impressive Q4 2025 financial results, indicating a 10% revenue growth year-over-year and a favorable outlook for 2026.
• Investor confidence in the company has been reinforced by its emphasis on the cystic fibrosis segment, successful product launches including KASJEVY and Gernavix, and advancements in other areas such as the renal pipeline with a focus on Povatacept for IgA nephropathy.
• Analysts' generally positive outlook on Vertex Pharmaceuticals, as reflected in a high average 12-month price target and favorable expert opinions, has further bolstered the bullish market sentiment.
• The purchase of Vertex Pharmaceuticals shares by ING Groep NV and other institutional investors indicates a strong belief in the company's future growth potential, underlining the positive sentiment prevailing in the market.

06.00.2026 - VRTX Stock was up 5.2%

• Vertex Pharmaceuticals was upgraded by Wolfe Research from "peer perform" to "outperform," with a price target of $548, reflecting optimism about the company's future.
• The company exceeded quarterly earnings expectations, showing strong growth in EPS and revenue, indicating a solid financial performance and potential for further advancement.
• Institutional investors demonstrate continued enthusiasm for Vertex Pharmaceuticals despite insider selling, holding a considerable portion of the company's stock, potentially boosting market confidence.
• The bullish trend in Vertex Pharmaceuticals can be linked to Wolfe Research's upgrade, the company's impressive financial results, and the sustained interest from institutional investors, indicating a positive sentiment towards its growth prospects in the biopharmaceutical industry.

06.00.2026 - VRTX Stock was up 5.0%

• The company was upgraded from "peer perform" to "outperform" by Wolfe Research with a price target of $548, reflecting a positive outlook on its growth prospects.
• Vertex exceeded quarterly earnings estimates with $4.80 EPS and $3.08 billion in revenue, showing 11% year-over-year growth, which contributed to the bullish sentiment.
• Despite insider selling activity, institutional investors owning a significant portion of the company's stock indicate strong confidence in its future performance.
• The upgrade and positive earnings results likely fueled investor optimism and buying interest in Vertex Pharmaceuticals, driving the stock price higher.

10.02.2026 - VRTX Stock was up 10.5%

• Vertex Pharmaceuticals stock surged 5% after successful Phase 3 trial results for its kidney disease drug, povetacicept, showing promising efficacy and safety profile.
• The company's $4.9 billion acquisition of a biotech company focused on kidney disease is nearing an important milestone, suggesting potential positive outcomes for its investment.
• Increased stake by Capital Research Global Investors and positive reactions from analysts indicate growing confidence in Vertex's pipeline and future commercial prospects.
• Market Linked Securities offering by Goldman Sachs Group Inc. linked to Adobe Inc. and CoreWeave, Inc. stocks may have also influenced positive market sentiment towards Vertex Pharmaceuticals, contributing to its bullish movement.

10.02.2026 - VRTX Stock was up 9.4%

• VRTX stock surged by 5% following successful Phase 3 trial results for its kidney disease drug, povetacicept, which showed promising efficacy in reducing proteinuria and maintaining a clean safety profile.
• The positive trial results have sparked investor optimism, leading to an increase in Vertex's stock price and attracting the attention of major institutional investors like Capital Research Global Investors, who have been increasing their stake in the company.
• Analysts have reacted positively to the news, raising price targets for Vertex as the successful drug trial signifies a potential new revenue stream beyond the company's established cystic fibrosis business.
• The bullish movement in VRTX stock also outperformed the broader market, with S&P 500 futures remaining steady in premarket trading, further underscoring the positive sentiment surrounding Vertex Pharmaceuticals.

10.02.2026 - VRTX Stock was up 10.7%

• Vertex Pharmaceuticals experienced a strong bullish movement today, with its stock jumping significantly.
• The positive Phase 3 clinical trial data for its kidney disease drug was a key driver of the stock's rise.
• Reduction in stake by a financial group might have initially raised concerns, but the successful drug trial results reassured investors and led to a rally in the stock.
• Positive sentiment towards the drug's performance from financial analysts further fueled the market's reaction, indicating confidence in Vertex's pipeline and future prospects.

21.00.2026 - VRTX Stock was up 5.0%

• Vertex Pharmaceuticals is a leading biotech company known for its strong cystic fibrosis franchise and innovative therapies. The stock had a bullish movement today amidst positive market sentiment.
• A prominent financial firm reduced its stake in VRTX, but insiders have been selling shares, indicating confidence in the company's performance.
• Analysts maintain a "Moderate Buy" rating with an average target price of $503.80, reflecting optimism in the stock's potential.
• The upcoming announcement of fourth-quarter and full-year 2025 financial results on February 12th creates anticipation and interest among investors.
• Despite recent mixed performance, the stock's undervaluation potential of up to 39% according to a discounted cash flow model could be driving investor interest and contributing to the bullish movement.